Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$3.1 - $4.32 $883 - $1,231
-285 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$7.76 - $10.43 $1,683 - $2,263
217 Added 319.12%
285 $3,000
Q4 2020

Feb 12, 2021

SELL
$4.13 - $10.14 $2,300 - $5,647
-557 Reduced 89.12%
68 $1,000
Q3 2020

Nov 12, 2020

BUY
$3.91 - $7.15 $2,443 - $4,468
625 New
625 $3,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.